Epidemiologists and virologists are moving away from the term "booster" to describe COVID-19 vaccines, according to a July 26 ABC News report. 

The FDA is warning healthcare providers of dosing errors associated with compounded versions of semaglutide, the active ingredient in Ozempic, Rybelsus and Wegovy.

Ozempic and other GLP-1 medications are increasingly affecting hospital operations and the U.S. healthcare industry. 

Walmart has opened 25 new autoimmune-focused specialty pharmacies across the U.S.

Walgreens has received $25 million in federal funding to conduct a decentralized clinical trial on COVID-19 vaccine immunity. 

On July 17, Roche published early results from a phase 1 trial of an experimental GLP-1 pill for obesity. That day, the drugmaker gained $16.8 billion in its market value, Bloomberg reported. 

Compared to a year prior, more pharmacists, physicians, physician assistants and nurse practitioners agree that pharmacists should have more primary care duties, according to a survey conducted by Surescripts. 

On July 22, Hikma Pharmaceuticals announced a voluntary recall of one lot of intravenous bags after a reported adverse event.

An investigation by federal lawmakers found that pharmacy-benefit managers promised to control costs but have instead steered patients toward higher-priced medicines and affiliated pharmacies that reduce patient choice, The Wall Street Journal reported July 23.

Endo USA is voluntarily recalling one lot of clonazepam because of mislabeled strength information, the FDA said July 17.